Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism
Use of18F-DOPA PET/MRI for the Detection and Localization of Focal Forms of Hyperinsulinism
Washington University School of Medicine
100 participants
Sep 10, 2020
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET/MRI as a preoperative tool to detect and localize focal lesions in the pancreas that are causing hyperinsulinism.
Eligibility
Inclusion Criteria5
- Patients with confirmed hyperinsulinemic hypoglycemia, diagnosed by elevated insulin levels during hypoglycemia and/or response to glucagon stimulation.
- Subjects who failed pharmacological therapy with diazoxide or octreotide.
- Subjects with signed informed consent by themselves or their parents or legal guardians.
- Patient's Endocrinologist has determined that the patient cannot be safely managed with standard medical therapy (failed) and surgery is recommended to prevent future episodes of severe hypoglycemia and preserve brain function.
- Cases in which surgery will not be considered by parents or guardians.
Exclusion Criteria1
- Any other major illness or condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in this study.
Interventions
The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05088798